Connor, Clark & Lunn Investment Management Ltd. Castle Biosciences Inc Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.1 Billion
- Q1 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Castle Biosciences Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 176,889 shares of CSTL stock, worth $3.01 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
176,889
Previous 168,713
4.85%
Holding current value
$3.01 Million
Previous $4.5 Million
21.24%
% of portfolio
0.02%
Previous 0.02%
Shares
12 transactions
Others Institutions Holding CSTL
# of Institutions
192Shares Held
26.6MCall Options Held
9.5KPut Options Held
5K-
Black Rock Inc. New York, NY3.04MShares$51.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.05MShares$34.8 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.47MShares$25 Million0.02% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.27MShares$21.5 Million2.07% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.2MShares$20.4 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $448M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...